NeoMed Management Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
5
- Investments
-
79
- Portfolio
-
4
- Exits
-
50
NeoMed Management General Information
Description
Founded in 1997, NeoMed Management is a venture capital firm based in Oslo, Norway. The firm focuses on investments in the healthcare, pharmaceutical, medical device and diagnostic sectors. It invests predominantly in Europe and selectively in North America in companies.
Contact Information
Website
www.neomed.net
Year Founded
1997
Investor Status
Actively Seeking New Investments
Trade Association
Principles for Responsible Investment (PRI)
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
- IFC 5
- St Helier, NJ
- United States
NeoMed Management Investments (79)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Oxular | 01-Mar-2021 | Later Stage VC | 000.00 | Drug Discovery | Generating Revenue | 0000 00000 00.0 |
| 000000000 00000000 | 05-Feb-2020 | 00 000000000 | 0000 | Therapeutic Devices | Generating Revenue | 0000 00000 00.0 |
| 0000000 0000000 | 22-Jan-2020 | 0000 | 000.00 | Therapeutic Devices | Generating Revenue/Not Profitable | 000000 000000 00.0 |
| 0000000 | 26-Dec-2019 | 00 000000000 | 000.00 | Surgical Devices | Generating Revenue/Not Profitable | |
| 000 0000000 000000 | 18-Oct-2018 | 0000000000 | Enterprise Systems (Healthcare) | Generating Revenue | 0000 00000 00.0 | |
| 00 000000000000000 | 21-Sep-2018 | 00000 00000 | 0000 | Biotechnology | Generating Revenue/Not Profitable | |
| 0000000 | 11-Apr-2018 | 00000 00000 | 000.00 | Therapeutic Devices | Generating Revenue/Not Profitable | 0000 00000 00.0 |
| 0000000 | 18-Sep-2017 | 00 000000000 | 0000 | Surgical Devices | Generating Revenue/Not Profitable | 0000 00000 00.0 |
| Avitide | 26-Jun-2017 | Later Stage VC | 0000 | Biotechnology | Generating Revenue | 0000000 00000 00.0 |
| Sonendo | 16-May-2017 | Later Stage VC | 0000 | Surgical Devices | Generating Revenue/Not Profitable | 0000 00000 00.0 |
NeoMed Management Exits (50)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Gelesis | 13-Jan-2022 | Reverse Merger | 00000 |
| 0000000 | 29-Oct-2021 | 000 | 000.00 |
| 0000000 | 30-Sep-2021 | 000000000000000000 | 00000 |
| 0000000000 | 05-Feb-2021 | 000 | 00000 |
| 00000000 | 18-Jan-2021 | 000 00 00000000 | |
| 000000 00000000000 | 17-Sep-2019 | 0000000000: 000000 | |
| 0000000 0000000 | 11-Feb-2019 | 000 | 000.00 |
| 0000000 | 31-Oct-2018 | 000 | 00000 |
| Wilson Therapeutics | 25-May-2018 | Merger/Acquisition | 00000 |
| TandemLife | 04-Apr-2018 | Merger/Acquisition | 00000 |
NeoMed Management Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
NeoMed Management Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
NeoMed Management Team (13)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Dina Chaya Ph.D | Partner | 0 | 0 | 0 | Geneva, Switzerland |
| Thomas Goebel Ph.D | Principal | 0 | 0 | 0 | Geneva, Switzerland |
| Pål Jensen | Director of Finance | 0 | Oslo, Norway | ||
| Erik Amble Ph.D | Founder, Partner & Chairman | 00 | 0 | 0 | Oslo, Norway |
| Claudio Nessi Ph.D | Managing Partner | 00 | 0 | 0 | Geneva, Switzerland |
NeoMed Management Co-Investors (3)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Forbion | 1 | 0 |
|
|
|
| IP Group | 0 | 0 |
|
|
|
| V-Bio Ventures | 0 | 0 |
|
|